Premature infants are born prior to a critical window of rapid placental nutrient transfer and fetal growth—particularly brain development—that occurs during the third trimester of pregnancy. Subsequently, a large proportion of preterm neonates experience extrauterine growth failure and associated neurodevelopmental impairments. Human milk (maternal or donor breast milk) is the recommended source of enteral nutrition for preterm infants, but requires additional fortification of macronutrient, micronutrient, and energy content to meet the nutritional demands of the preterm infant in attempts at replicating in utero nutrient accretion and growth rates. Traditional standardized fortification practices that add a fixed amount of multicomponent fortifier based on assumed breast milk composition do not take into account the considerable variations in breast milk content or individual neonatal metabolism. Emerging methods of individualized fortification—including targeted and adjusted fortification—show promise in improving postnatal growth and neurodevelopmental outcomes in preterm infants.
Objectives The impact of crucial early parenteral nutrition on neurometabolism of the preterm brain remains unclear. This study characterizes the relationship of parenteral lipid and caloric intake with cerebellar neurometabolites. Methods Very premature infants [born ≤32-week gestational age (GA)] in a prospective observational cohort study underwent a proton magnetic resonance spectroscopy (1H-MRS) acquisition from a cerebellar voxel at term-age. Parenteral lipid and caloric intake (g/kg/d or kcal/kg/d) in the first 4 weeks of life were calculated by chart review. Results 48 preterm infants born at 28.3 ± 2.4 weeks GA underwent 1H-MRS at 38.9 ± 1.9 weeks postmenstrual age. Cerebellar N-acetylaspartate [NAA] positively correlated with 4-week parenteral lipid (Rho = 0.4, p = 0.005) and caloric (Rho = 0.3, p = 0.047) intake. Glutamate [Glx] demonstrated a positive trend. Adjusted for covariates, 4-week parenteral lipid intake was associated with higher NAA (B coefficient = 0.89, p = 0.003) and Glx (B = 1.72, p = 0.045). Conclusions Parenteral lipid intake is associated with higher cerebellar NAA and Glx concentrations, supporting brain development in preterm infants.
To identify the timing and clinical risk factors associated with somatic growth faltering (GF) in very preterm infants (VPI, born < 32 weeks' gestation) and explore the relationship with longitudinal brain growth throughout the extrauterine second and third trimesters. Observational cohort followed with serial growth anthropometrics and brain magnetic resonance imaging at approximately 4-week intervals through term corrected age. Multivariable logistic regression identified clinical covariates associated with GF. Generalized additive models, extended linear mixed models, and multivariable linear mixed models were applied to create trajectories of nutritional intake and weight and brain growth and compare term corrected brain volumes between VPI with and without GF. 118 VPI (68 GF, 50 no GF) underwent 333 magnetic resonance imaging studies (195 GF, 138 no GF). Those with GF were born younger (mean [SD] 27.4 [2.2] vs 28.3 [2.3] weeks, p=0.02) and experienced more clinical comorbidities. Poor weight gain in GF VPI began after 33 weeks corrected age and was associated with early systemic steroids (odds ratio [95% CI] 3.8 [1.2,14.8], P=0.03) and gastrointestinal surgery (odds ratio [95% CI] 7.8 [1.8,53.9], P=0.01). GF infants demonstrated significantly lower lipid, caloric, and maternal milk intake trajectories than non-GF infants. VPI with GF compared with no GF experienced slower volumetric brain growth after 37 weeks corrected age in nearly all brain regions. Term corrected cerebellar (β= -1.74 [-2.95,-0.52], p=0.01) and brainstem (β= -0.29 [-0.55,-0.04], p=0.02) volumes were lower in GF infants after adjusting for significant covariates. Brain growth is impaired during critical extrauterine periods in GF VPI, with a 4-week interval between the onset of weight faltering and subsequent brain growth deceleration that may represent an important window for clinical intervention.